Literature DB >> 11413511

Low bone mineral density in hormone-naïve men with prostate carcinoma.

M R Smith1, F J McGovern, M A Fallon, D Schoenfeld, P W Kantoff, J S Finkelstein.   

Abstract

BACKGROUND: The objective of this study was to determine the prevalence of low bone mineral density in men with prostate carcinoma and no history of androgen-deprivation therapy.
METHODS: The authors conducted a cross-sectional study in 41 hormone-naïve men with locally advanced, lymph node positive, or recurrent prostate carcinoma and no radiographic evidence of bone metastases. Bone mineral density of the total hip, posterior-anterior (PA) lumbar spine, and lateral lumbar spine was determined by dual-energy X-ray absorptiometry (DXA) using a densitometer. Trabecular bone mineral density of the lumbar spine was determined by quantitative computed tomography (QCT). Bone mineral density results were expressed in standard deviation units relative to young adult men (T score) and relative to age-matched men (Z score).
RESULTS: Fourteen of 41 men (34%; 95% confidence interval [95% CI], 20-51%) had T scores < -1.0 at one or more skeletal sites by DXA, 12 of 41 men (29%; 95% CI, 16-42%) had T scores between -1.0 and -2.5, and 2 of 41 men (5%; 95% CI, 1-17%) had T scores < -2.5. Thirty-nine of 41 men (95%; 95% CI, 83-99%) had T scores < -1.0 by QCT, 13 of 41 men (31%; 95% CI 18-48%) had T scores between -1.0 and -2.5, and 26 of 41 men (63%; 95% CI, 47-78%) had T scores < -2.5. T scores for trabecular bone mineral density of the lumbar spine were significantly lower than T scores for either the total hip (P < 0.001) or the PA lumbar spine (P < 0.001). The mean Z score for trabecular bone mineral density of the lumbar spine was -0.7 +/- 0.9. Hypogonadism, hypovitaminosis D, and dietary calcium intakes below the Recommended Daily Allowance were observed in 20%, and 17%, and 59% of study participants, respectively.
CONCLUSIONS: Many hormone-naïve men with prostate carcinoma have low bone mineral density. QCT is a more sensitive method than DXA for diagnosing low bone mineral density in this patient population. Trabecular bone mineral density is lower than expected for age and risk factors for osteoporosis are common. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413511

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Preventing skeletal complications in androgen deprived men with prostate cancer: Time for action.

Authors:  M Braga-Basaria; S Basaria
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Adverse events associated with hormonal therapy for prostate cancer.

Authors:  Ravi J Kumar; Al Barqawi; E David Crawford
Journal:  Rev Urol       Date:  2005

3.  Fracture risk in patients with prostate cancer on androgen deprivation therapy.

Authors:  Ana M López; María A Pena; Rafael Hernández; Fernando Val; Bernardo Martín; José A Riancho
Journal:  Osteoporos Int       Date:  2005-02-16       Impact factor: 4.507

4.  A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.

Authors:  C E Lee; W D Leslie; P Czaykowski; J Gingerich; M Geirnaert; Y K J Lau
Journal:  Curr Oncol       Date:  2011-08       Impact factor: 3.677

Review 5.  Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy.

Authors:  Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright
Journal:  Endocrine       Date:  2015-01-31       Impact factor: 3.633

6.  Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study.

Authors:  May Darwish-Yassine; Manijeh Berenji; Diane Wing; Glenn Copeland; Raymond Y Demers; Carol Garlinghouse; Angela Fagerlin; Gail E Newth; Laurel Northouse; Margaret Holmes-Rovner; David Rovner; Jerry Sims; John T Wei
Journal:  J Cancer Surviv       Date:  2013-11-10       Impact factor: 4.442

Review 7.  Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.

Authors:  Ary Serpa Neto; Marcos Tobias-Machado; Marcos A P Esteves; Marília D Senra; Marcelo L Wroclawski; Fernando L A Fonseca; Rodolfo B dos Reis; Antônio C L Pompeo; Auro Del Giglio
Journal:  BMC Urol       Date:  2010-05-19       Impact factor: 2.264

9.  A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.

Authors:  Sung Joon Hong; Kang Su Cho; Han Yong Cho; Hanjong Ahn; Choung-Soo Kim; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

10.  Use of bisphosphonates in prostate cancer: Current status.

Authors:  Rishi Nayyar; Narmada P Gupta
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.